Endometrial Cancer

A subgroup analysis of ENGOT-EN6-NSGO/GOG-3031/RUBY has displayed positivity efficacy in patients with advanced/recurrent endometrial cancer.

Closing out his review of treatment options in the setting of recurrent endometroid adenocarcinoma, Matthew A. Powell, MD, highlights unmet needs and future directions in care.

Expert perspectives on second-line treatment approaches to endometroid adenocarcinoma, with deference to data from the KEYNOTE-775 clinical trial.

Centering discussion on first-line therapy in endometroid adenocarcinoma, Matthew A. Powell, MD, highlights molecular targets and treatment options in this setting.

Expert Matthew A. Powell, MD, reviews the diagnosis, treatment, and recurrence of a 71-year-old woman who presents with endometroid adenocarcinoma.

Closing out their program on endometrial carcinoma management, key opinion leaders highlight key novel therapeutic strategies in the evolving treatment landscape.

Collaborative discussion on the advent of triplet therapy in patients with metastatic uterine serous carcinoma and clinical data behind this strategy.

John Nakayama, MD, discusses what the evolution of endometrial cancer treatment has looked like in recent years.

Expert Robert L. Coleman, MD, details the final patient case and provides an overview of metastatic uterine serous carcinoma.

Key opinion leaders in the field of endometrial carcinoma provide advice on adverse event management, focusing on immune checkpoint inhibitor therapy.

The combination of lenvatinib and pembrolizumab continued to show benefits in efficacy vs chemotherapy among patients with endometrial cancer treated in Study 309/KEYNOTE-775.

Robert L. Coleman, MD, and Krishnansu S. Tewari, MD, reflect on data from the GARNET clinical trial of dostarlimab in dMMR recurrent endometrial carcinoma.

Shared insight on the utilization of pembrolizumab in dMMR recurrent endometrial carcinoma in the context of the KEYNOTE-158 clinical trial.

Closing out her discussion on the management of recurrent endometrial cancer, Ritu Salani, MD, MBA, shares clinical pearls amidst the shifting treatment paradigm.

A focused review of clinical trial data that inform the use of immune checkpoint inhibition in the setting of recurrent endometrial cancer.

An expert gynecologic oncologist shares her perspective on treatment options available to patients in the first- and second-line settings of endometrial cancer.

Opening her discussion on a patient case of recurrent endometrial cancer, Ritu Salani, MD, MBA, highlights the evolving role of molecular testing in this setting.

Robert L. Coleman, MD, opens discussion on a second patient case and highlights critical aspects of mismatch repair deficient (dMMR) recurrent endometrial carcinoma.

Before closing out their discussion on the first patient case, key opinion leaders on endometrial carcinoma reflect on the optimal selection and sequencing of therapy in pMMR recurrent disease.

A trial of TOS-358, a first-in-class covalent PI3Kα inhibitor, for various solid tumors dosed its first patient.

An artificial intelligence model has been shown to predict the risk of low and high distant recurrence in patients with endometrial cancer.

Wesley Burkett, MD, discusses some novel targets that are available and being evaluated in the endometrial cancer space.

Expert panelists provide their perspective on the real-world use of combination lenvatinib + pembrolizumab in patients with MMRp recurrent endometrial carcinoma.

Moderator Robert L. Coleman, MD, spearheads a review of clinical data from KEYNOTE 775, which combined lenvatinib with pembrolizumab in patients with endometrial carcinoma.

The addition of dostarlimab to standard combination chemotherapy in the phase 3 RUBY study showed a significant survival improvement in patients with primary advanced or recurrent endometrial cancer.

During a Targeted Oncology™ Case-Based Roundtable™, Robert W. Holloway, MD, discussed with participants later-line systemic therapy options for patients with recurrent/metastatic endometrial cancer.

Key opinion leaders in the field of endometrial carcinoma management share advice on optimal patient monitoring and the identification of recurrent disease.

Shared insight on the advent of molecular testing in patients with endometrial carcinoma and how it helps inform the treatment pathway.

Experts Michael J. Birrer, MD, PhD, and Kimberly Halla, MSN, FNP-C, share insight to a typical patient presentation of MMRp recurrent endometrial carcinoma.

Opening its discussion on endometrial carcinoma, a panel of experts led by Robert L. Coleman, MD, reflects on a patient with mismatch repair proficient (MMRp) recurrent disease.